Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.72
-1.1%
$1.73
$1.32
$2.72
$254.11M1.6672,270 shs62,249 shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$10.12
+1.5%
$9.94
$3.90
$14.67
$849.68M1.691.16 million shs942,341 shs
ProKidney Corp. stock logo
PROK
ProKidney
$2.82
+1.8%
$1.78
$0.46
$7.13
$810.77M1.2638.09 million shs1.32 million shs
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$11.13
$9.30
$2.86
$11.40
$992.13M2.233.94 million shsN/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-1.15%0.00%+1.18%+0.58%-20.37%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
+1.50%-11.54%-4.98%+78.48%-9.64%
ProKidney Corp. stock logo
PROK
ProKidney
+1.81%-14.29%+387.30%+257.32%+20.51%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
0.00%-0.67%-0.71%+114.45%+59.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
1.4148 of 5 stars
3.52.00.00.01.80.00.0
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
4.5686 of 5 stars
4.51.00.04.43.03.30.6
ProKidney Corp. stock logo
PROK
ProKidney
3.2573 of 5 stars
3.24.00.00.02.93.30.6
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
3.3457 of 5 stars
4.24.00.00.02.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00306.98% Upside
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
3.00
Buy$18.5783.51% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.40
Hold$6.25121.63% Upside
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
2.33
Hold$14.5730.92% Upside

Current Analyst Ratings Breakdown

Latest IMMP, VERV, ORIC, and PROK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
ProKidney Corp. stock logo
PROK
ProKidney
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $8.00
7/14/2025
ProKidney Corp. stock logo
PROK
ProKidney
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $7.00
7/9/2025
ProKidney Corp. stock logo
PROK
ProKidney
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $9.00
7/8/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
6/30/2025
ProKidney Corp. stock logo
PROK
ProKidney
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00 ➝ $1.00
6/27/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.50
6/26/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/23/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$20.00
6/18/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$28.00 ➝ $11.00
6/18/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$12.00
6/18/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$13.50
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M48.87N/AN/A$1.05 per share1.64
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/A$3.45 per shareN/A
ProKidney Corp. stock logo
PROK
ProKidney
$306K2,697.41N/AN/A($3.41) per share-0.83
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$32.33M30.69N/AN/A$5.83 per share1.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A8/29/2025 (Estimated)
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$127.85M-$1.87N/AN/AN/AN/A-51.14%-46.29%8/11/2025 (Estimated)
ProKidney Corp. stock logo
PROK
ProKidney
-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%8/14/2025 (Estimated)

Latest IMMP, VERV, ORIC, and PROK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$0.70N/AN/AN/A$4.26 millionN/A
8/11/2025Q2 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.46N/AN/AN/AN/AN/A
8/8/2025Q2 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million
5/12/2025Q1 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.16-$0.13+$0.03-$0.13N/A$0.23 million
5/5/2025Q1 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.51-$0.42+$0.09-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/A
12.00
12.00
ProKidney Corp. stock logo
PROK
ProKidney
N/A
10.96
10.96
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/A
9.84
9.84

Institutional Ownership

CompanyInstitutional Ownership
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
95.05%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
97.11%

Insider Ownership

CompanyInsider Ownership
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
6.82%
ProKidney Corp. stock logo
PROK
ProKidney
41.49%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
19.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
8085.22 million79.41 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
3292.70 million171.26 millionOptionable
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
11089.14 million71.94 millionOptionable

Recent News About These Companies

Gene Therapy Companies Set Sights on Cardiovascular Disease
Biotech lab
3 Bullish Biotech Stocks With Explosive Growth Trends
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.72 -0.02 (-1.15%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.72 0.00 (-0.29%)
As of 08/1/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Oric Pharmaceuticals stock logo

Oric Pharmaceuticals NASDAQ:ORIC

$10.12 +0.15 (+1.50%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.12 0.00 (0.00%)
As of 08/1/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ProKidney stock logo

ProKidney NASDAQ:PROK

$2.82 +0.05 (+1.81%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.82 +0.01 (+0.18%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Verve Therapeutics stock logo

Verve Therapeutics NASDAQ:VERV

$11.13 0.00 (0.00%)
As of 07/25/2025

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.